Eupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Increased to Strong-Buy at RODMAN&RENSHAW

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Separately, Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $9.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $2.90 on Thursday. Eupraxia Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $5.58. The firm has a market cap of $79.12 million and a price-to-earnings ratio of -4.03. The business’s fifty day moving average is $2.65 and its 200 day moving average is $2.68.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.